Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.534
EU - Europa 14.364
AS - Asia 7.092
SA - Sud America 425
AF - Africa 87
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 21
Totale 49.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.073
SG - Singapore 3.041
IT - Italia 2.883
RU - Federazione Russa 2.593
DE - Germania 2.484
CN - Cina 1.886
IE - Irlanda 1.762
SE - Svezia 1.611
HK - Hong Kong 1.149
UA - Ucraina 1.032
GB - Regno Unito 600
CA - Canada 436
BR - Brasile 349
FI - Finlandia 344
FR - Francia 293
ID - Indonesia 234
TR - Turchia 195
VN - Vietnam 188
IN - India 178
AT - Austria 131
DK - Danimarca 119
NL - Olanda 104
BE - Belgio 101
PL - Polonia 78
JP - Giappone 40
BG - Bulgaria 32
EU - Europa 32
CZ - Repubblica Ceca 30
ES - Italia 30
IR - Iran 30
KR - Corea 26
ZA - Sudafrica 26
RO - Romania 22
AR - Argentina 21
CH - Svizzera 20
LT - Lituania 19
MA - Marocco 16
MX - Messico 16
AU - Australia 15
GR - Grecia 14
PE - Perù 14
EG - Egitto 13
NO - Norvegia 13
PK - Pakistan 13
PT - Portogallo 13
BD - Bangladesh 12
EC - Ecuador 11
CL - Cile 10
KG - Kirghizistan 10
MU - Mauritius 10
PH - Filippine 10
CO - Colombia 9
MY - Malesia 8
IQ - Iraq 7
TN - Tunisia 7
NZ - Nuova Zelanda 6
RS - Serbia 6
AM - Armenia 5
AZ - Azerbaigian 5
EE - Estonia 5
IL - Israele 5
JO - Giordania 5
LV - Lettonia 5
SC - Seychelles 5
TH - Thailandia 5
UZ - Uzbekistan 5
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
SK - Slovacchia (Repubblica Slovacca) 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
KE - Kenya 3
LU - Lussemburgo 3
MD - Moldavia 3
PY - Paraguay 3
SA - Arabia Saudita 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CY - Cipro 2
HR - Croazia 2
KW - Kuwait 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
KH - Cambogia 1
Totale 49.548
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Woodbridge 2.706
Fairfield 2.295
Singapore 1.964
Dublin 1.718
Houston 1.601
Chandler 1.489
Frankfurt am Main 1.472
Ashburn 1.401
Wilmington 1.313
Milan 1.188
Hong Kong 1.137
Jacksonville 1.040
Seattle 931
Dearborn 794
Cambridge 784
Santa Clara 695
New York 669
Princeton 564
Nanjing 315
Shanghai 270
Moscow 262
Altamura 249
Lawrence 249
Beijing 233
Jakarta 225
Göttingen 188
Lachine 173
San Diego 137
Boardman 127
Guangzhou 124
Hefei 109
Toronto 105
Helsinki 103
Lissone 101
Andover 98
Brussels 97
Nuremberg 96
Nanchang 95
Dong Ket 91
Los Angeles 91
Munich 91
Ottawa 91
Shenyang 89
Vienna 85
Council Bluffs 80
Fremont 80
Hebei 68
Tianjin 67
Fürstenwalde 65
Romola 62
Rome 61
London 59
Jiaxing 56
Lodz 52
Jinan 49
Falls Church 48
Norwalk 46
Kocaeli 45
Changsha 44
Chicago 44
Kunming 42
Mountain View 42
Pune 41
Düsseldorf 40
Turku 38
Redmond 37
Edmonton 35
Hangzhou 32
Huizen 31
The Dalles 31
Washington 30
Desio 29
Cinisello Balsamo 27
Monza 27
Dallas 26
Kiev 26
Zhengzhou 25
Turin 24
São Paulo 23
Bologna 22
Lauterbourg 21
Ningbo 21
Pavia 20
Plovdiv 20
Bonndorf 19
Carate Brianza 19
Lappeenranta 18
Como 17
San Francisco 17
Bari 16
Buffalo 16
Detroit 16
Kilburn 16
Nürnberg 16
Portsmouth 16
San Mateo 16
St Petersburg 16
Brooklyn 15
Leawood 14
Totale 35.712
Salva come PNG Salva come JPEG
Nome #
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 440
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 429
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 384
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 381
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 373
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 338
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 335
Acute myeloid leukaemia niche regulates response to L-asparaginase 332
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 331
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 330
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 323
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 321
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 320
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 311
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 307
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 305
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 293
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 292
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 291
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 291
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 290
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 289
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 287
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 285
Imatinib long term effects study: three years of follow-up and assessment 283
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 283
Chronic myeloid leukemia: Second-line drugs of choice 280
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 279
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 277
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 272
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 264
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 249
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 245
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 244
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 244
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 234
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 234
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 233
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 231
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 230
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 228
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 226
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 226
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 226
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 226
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 224
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 223
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 222
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 219
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 216
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 215
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 214
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 214
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 213
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 213
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 212
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 212
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 212
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 210
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 209
Reply to P. Laneuville et al 208
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 207
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 206
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 205
ALK inhibitors for clinical use in cancer therapy 204
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 203
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 203
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 203
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 202
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 202
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 202
Inhibition of RET tyrosine kinase by SU5416 202
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 199
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 199
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 197
Whole-Exome Sequencing Data - Identifying Somatic Mutations 197
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 196
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY 196
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 195
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 193
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 192
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 192
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 189
Expression, purification, and inhibition of human RET tyrosine kinase 188
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 188
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 187
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 183
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 181
The ALK gene, an attractive target for inhibitor development 181
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 180
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 180
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 180
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 180
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 179
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 179
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 178
Differences among young adults, adults and elderly chronic myeloid leukemia patients 178
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 178
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 177
The role of bosutinib in the treatment of chronic myeloid leukemia 177
Totale 23.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 185.098
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.098
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020660 0 0 0 0 0 0 0 0 0 0 492 168
2020/20217.402 336 311 901 756 605 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/202510.904 790 1.498 734 665 1.115 506 914 419 1.112 1.954 1.197 0
Totale 51.354